Results 81 to 90 of about 4,490 (182)

ENTRECTINIB AND LAROTRECTINIB: CANCER-AGNOSTIC THERAPY

, 2022
reservednel 2021, l'AIFA ha approvato due nuovi farmaci, entrectinib e larotrectinib, che hanno l'innovazione di essere agnostici: danneggiano il tessuto tumorale indipendentemente dall'organo colpito, ma in base a mutazioni geniche che portano alla ...
BORDIGNON, ANGELA
core  

Supplementary materials: Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC

, 2021
These are supplementary materials for the article 'Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC' published in the Journal of Comparative Effectiveness Research.Supplementary ...
Huong Trinh (5120321), Michael Martinec (5828477), Reynaldo Martina (7754501), Laura Perez (3414401), Robert C. Doebele (14937609), Todd Riehl (11325454), Matthew G. Krebs (16501923), William B Wong (17729130), Gracy Crane (5828483), Neal J Meropol (17729128)   +9 more
core   +1 more source

Supplementary Figures 1-6 and Tables 1-2 from Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

, 2016
Supplementary Figure 1. Efficacy of entrectinib on KM12 xenograft model using the scheduling 4 days on/ 3 days off. Supplementary Figure 2. Mechanism of action of entrectinib compared to crizotinib in ALK-dependent Ba/F3 cells.
Eduard Felder (1697959), Maria Beatrice Saccardo (2581243), Paolo Orsini (1533286), Jason Harris (60019), Antonella Isacchi (75227), Elena Ardini (2275171), Cristina De Ponti (15074364), Jean-Michel Vernier (3018930), Enrico Pesenti (387267), Roberta Bosotti (75220), David Anderson (533423), Arturo Galvani (1533352), Paola Magnaghi (1697968), Anna Degrassi (3214410), Daniele Casero (15074370), Romana Pulci (15074367), Nilla Avanzi (1697995), Luca Mologni (114485), Nadia Amboldi (387261), Dario Ballinari (2256394), Marina Ciomei (1533355), Maria Menichincheri (2256412), Gemma Texido (387259), Patrizia Banfi (2581258), Gang Li (34549), Daniele Donati (1533319), Tiziano Bandiera (1528006), Ge Wei (7902548)   +27 more
core   +1 more source

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors

Therapeutics and Clinical Risk Management, 2018
Dazhi Liu,1 Michael Offin,2 Stephen Harnicar,1 Bob T Li,2 Alexander Drilon2 1Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine ...
Liu D, Offin M, Harnicar S, Li BT, Drilon A   +4 more
doaj  

Supplementary materials: Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers

These are peer-reviewed supplementary materials for the article 'Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers' published in the Journal of Comparative Effectiveness Research ...
Josh Carlson (18499002), Todd Williamson (13278408), Kangho Suh (18498999), Sean Sullivan (1996342), Fang Xia (146439)   +4 more
core   +1 more source

Figure S3 from Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model

, 2020
Principle Components Analysis (PCA) of entrectinib resistant cell lines showing clustering of resistant cell lines as compared to parental cell ...
Koumudi Naraparaju (3760693), Venkatadri Kolla (52076), Radhika Iyer (3760702), Peng Guan (102746), Yuxuan Hu (398099), Suzanne P. MacFarland (14944425), Garrett M. Brodeur (6647798), Kai Tan (15072247)   +7 more
core   +1 more source

Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report

Frontiers in Oncology
The management of non-small cell lung cancer (NSCLC), specifically targeting the anaplastic lymphoma kinase (ALK) with tyrosine kinase inhibitors (TKIs), is challenged by the emergence of therapeutic resistance.
Dan Li, Yue Zhu, Jincheng Song, Dafu Yang, Saiqiong Cui, Xin Liu, Le Wang, Jiangyan Zhang, Evenki Pan, Zhaoxia Dai   +9 more
doaj   +1 more source

Case Report: Therapeutic biopsy guided targeted therapy improves visual acuity and prolongs survival in bilateral uveal metastases as the initial presentation of lung adenocarcinoma

Frontiers in Medicine
BackgroundAlthough uveal metastasis is common in lung cancer, reports of bilateral uveal metastasis as the initial symptom in lung adenocarcinoma patients undergoing intraocular biopsy are rare.
Tongtong Ou, Yiliu Yang, Chengda Ren, Fang Lu   +3 more
doaj   +1 more source

Entrectinib Shows Pediatric Potential [PDF]

Cancer Discovery, 2019
Abstract According to preliminary data from the phase I/Ib STARTRK-NG trial, the investigational multikinase inhibitor entrectinib showed efficacy in children and adolescents with CNS and other tumor types harboring NTRK1/2/3, ROS1, or ALK fusions. Durable responses were seen even in CNS tumors such as high-grade glioma.
openaire   +1 more source

Tumor-Agnostic Drugs and Precision Oncology

openNuove frontiere terapeutiche sono state investigate nell'ambito del trattamento dei tumori. Se inizialmente si prediligeva un approccio paziente-centrico, in cui erano le caratteristiche istologiche del tumore a condizionare la scelta terapeutica ...
BORGATO, DAVIDE
core